Why Trump’s new pick for Fed chair hit gold and silver markets – for good reasons 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Asian Currencies Trade Flat as Dollar Retreats After Fed Decision 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
US pharmaceutical giant Eli Lilly would cut the cost of its insulin by 70 percent through a series of steps, such as capping out-of-pocket costs at $35 per month for people with insurance.
However, while the US$35 cap takes effect immediately, other measures will be implemented later in the year.
According to the Indianapolis-based Lilly, they are taking actions to make it easier for Americans to access their insulin and help those having ”difficulty navigating a complex healthcare system."
US president Joe Biden called on other pharmaceutical firms to follow suit, noting that it's “flat wrong” to force Americans to pay over $300 for insulin, which costs less than $10 to make.
A centerpiece is the 70 percent price drop in Humalog, Lilly's most commonly prescribed insulin.
According to a 2020 Rand Corporation study, Insulin prices in the US have soared 8 times more than in 32 comparable high-income countries.
But much of the bounty from lofty prices do not go to pharma firms but is passed on to health insurers in the form of rebates.
